GlassScriptPhysician profile
William W Chow
NPI 1457409211
$12,858.90
in general payments reported to CMS, 2019-2025
47 companies · $1,567 in 2025
The $1,567 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,412 · 2020: $721 · 2021: $3,378 · 2022: $2,070 · 2023: $1,982 · 2024: $1,728 · 2025: $1,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,265 · Education: $13.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,264.60 |
| Education | $13.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,026.56 | 2019-2025 | Zilbrysq, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,759.35 | 2019-2025 | |
| Catalyst Pharmaceuticals, INC. | $1,500.00 | 2021 | |
| Genzyme Corporation | $859.52 | 2019-2023 | |
| Biogen, INC. | $610.91 | 2019-2024 | Tysabri, Vumerity |
| Lundbeck LLC | $596.57 | 2020-2025 | Vyepti |
| Abbott Laboratories | $571.38 | 2019-2024 | Infinity |
| Abbvie INC. | $566.74 | 2021-2023 | Ubrelvy, Qulipta |
| Argenx US, INC. | $500.81 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $442.91 | 2023-2025 | |
| Lilly USA, LLC | $432.39 | 2019-2025 | Amyvid, Kisunla |
| Sumitomo Pharma America, INC. | $301.77 | 2023-2024 | Aptiom |
| Acadia Pharmaceuticals INC | $257.17 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $227.57 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $200.47 | 2022-2025 | Rytary, Crexont |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.